PIK3CD and B-cell chronic lymphocytic leukemia: PI3K inhibitors have recently received increased attention in blood cancers, where an inhibitor of the p110δ catalytic isoform (idelalisib) elicits significant patient responses in both chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma [1].